News
-
-
COMMUNIQUÉ DE PRESSE
Rektron Schedules Annual General and Special Meeting of Shareholders in Response to Shareholder Requisition
Rektron Group Inc. announces annual general and special meeting in response to Concerned Shareholders' requisition for changes in the Board of Directors. Shareholders to receive details via management circular. The Company specializes in global commodity trading with a focus on energy and metals products -
COMMUNIQUÉ DE PRESSE
Line5 Earns Top Honors for Fourth Consecutive Year at the 2024 Dealers' Choice Awards
Line5 receives 2024 Dealers' Choice Awards Diamond Award for Excellence in F&I Product Financing for the seventh consecutive year. The company provides flexible financing options for automotive, RV, marine, and powersports industries -
-
COMMUNIQUÉ DE PRESSE
Communiqué : Orange - Information sur les opérations effectuées dans le cadre d’un programme de rachat d’actions, hors contrat de liquidité
Orange annonce l'acquisition d'actions propres dans le cadre de son programme de rachat d'actions 2024 pour les plans de rémunération des dirigeants. Aucun contrat de liquidité n'est impliqué -
-
COMMUNIQUÉ DE PRESSE
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany and 108% in September, leading to accelerated marketing efforts based on strong e-Rx metrics. Full-year 2024 guidance updated for increased marketing activity -
-
COMMUNIQUÉ DE PRESSE
Abivax annonce le recrutement d'un premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn
Abivax recrute premier patient pour Enhance-CD, essai clinique phase 2b obefazimod maladie Crohn. Etude 3 phases. Obefazimod, traitement prometteur -
COMMUNIQUÉ DE PRESSE
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
Abivax announces enrollment of first patient in Phase 2b trial of Obefazimod for Crohn's Disease, aiming for convenient, effective treatment option with fewer daily burdens
